A Stochastic Approach to LDL-C Intensification

Khaing Mar Lwin; Ata Ul Hayee Sohail; Oluwatomi Naomi Olukoya

A Stochastic Approach to LDL-C Intensification

Authors

Khaing Mar Lwin GMC
Ata Ul Hayee Sohail
Tomi

Keywords:

LDL-C, lipid intensification therapy, clinical benefit

Abstract

The transition from general guidelines to precision cardiovascular medicine requires tools that can model individual biological variance. This paper outlines the methodology of LipidLogic Pro v2.1, a simulation engine for predicting Absolute Risk Reduction (ARR) and Number Needed to Treat (NNT) following intensified lipid-lowering therapy. The engine utilizes a kinetic-based meta-regression approach derived from the Cholesterol Treatment Trialists’ (CTT) Collaboration.

References

1. Baigent C, et al. (Cholesterol Treatment Trialists’ Collaboration). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366(9493):1267-1278

2. Cannon CP, et al. (IMPROVE-IT Investigators). Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-2397.

3. Mach F, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.

4. Sabatine MS, et al. (FOURIER Steering Committee). Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722.